Immunome vs Xenetic Biosciences
IMNM and XBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMNM and XBIO compare
Immunome is the larger company, worth 517 times as much as Xenetic Biosciences ($2.0B against $3.8M).
Xenetic Biosciences grew revenue faster over the last twelve months (33.3% versus −63.3% for Immunome).
Xenetic Biosciences keeps more of each dollar of sales as profit, with a net margin of −75.9% compared with −5594% at Immunome.
Xenetic Biosciences scores higher on the StockData Score (12 against 7 for Immunome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMNM | XBIO |
|---|---|---|
| Size and price | ||
| Market cap | $2.0B | $3.8M |
| Share price | $17.18 | $1.61 |
| Change, 1 year | 0.23% | −38.1% |
| Change, 5 years | 1.2% | −88.9% |
| Beta (5Y) | 1.62 | 1.14 |
| Employees | 177 | 2 |
| StockData Score | ||
| Total score | 7 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 486× | 1.2× (better) |
| P/B | 3.3× | 0.6× (better) |
| FCF yield | −10.5% | – |
| Fair value | – | $4.53 |
| Margin of safety | – | 64.4% |
| Growth | ||
| Revenue growth (TTM) | −63.3% | 33.3% (better) |
| Revenue growth, 5Y average | – | 46.8% |
| Profitability | ||
| Operating margin | −5948% | −81.0% (better) |
| Net margin | −5594% | −75.9% (better) |
| FCF margin | −5119% | – |
| Return on equity | −50.1% | −47.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 21.68 (better) | 7.43 |
| Altman Z-score | 35.70 (better) | −37.70 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 104% | 6.5% |
| Held by insiders | 6.4% | 12.2% |
| Insider net buying, 12 months | −$25.2M | – |
| Short interest, % of float | 15.2% | 1.8% |
Go deeper
- IMNM stock overview
- IMNM income statement
- IMNM valuation and score
- XBIO stock overview
- XBIO income statement
- XBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.